癌症
- Rank: 7
- Volume: 2,000+
- Increase: —
- Started: 2026-09-09T20:30:00+08:00
- Status: 活躍
- Report date: 2026-09-10
- Source: https://tw.news.yahoo.com/%25E8%258E%25AB%25E5%25BE%25B7%25E7%25B4%258D%25E7%2599%258C%25E7%2597%2587%25E7%2596%25AB%25E8%258B%2597%25E4%25B8%2589%25E6%259C%259F%25E9%2581%2594%25E6%25A8%2599-%25E5%25A4%25A9%25E6%2598%258E%25E8%25A3%25BD%25E8%2597%25A5%25E5%25B8%2583%25E5%25B1%2580%25E9%25BB%2591%25E8%2589%25B2%25E7%25B4%25A0%25E7%2598%25A4til%25E7%25B4%25B0%25E8%2583%259E%25E6%25B2%25BB%25E7%2599%2582-153529037.html
主要內容摘要
1. 莫德納 mRNA 癌苗三期達主要與關鍵次要終點
2. 試驗聚焦術後高復發風險黑色素瘤患者
3. 天明製藥布局 TIL，製備中心具 GTP 認可
為何成為話題
個人化免疫治療達標拉高治癒期待，影響生技股評價、臨床轉譯速度與國內精準醫療產業布局。
三個爭議點
1. 完整數據未公開能否過度解讀達標
2. mRNA 與 TIL 路線資源是否排擠
3. GTP 場所認證易被誤解為療效已核准